Andressa Chequin, Luiz E Costa, Felipe F de Campos, Angie D B Moncada, Lucas T F de Lima, Lucas R Sledz, Guilherme F Picheth, Eliana R Adami, Alexandra Acco, Marcos B Gonçalves, Graciele C M Manica, Gláucio Valdameri, Lucia de Noronha, José E Q Telles, Elisa H F Jandrey, Erico T Costa, Fabricio F Costa, Emanuel M de Souza, Edneia A S Ramos, Giseli Klassen
Breast cancer (BC) is the most frequently diagnosed female cancer and second leading cause of death. Despite the discovery of many antineoplastic drugs for BC, the current therapy is not totally efficient. In this study, we investigated the potential of repurposing the well-known diabetes type II drug liraglutide to modulate epigenetic modifications in BC cells lines in vitro and in vivo via Ehrlich mice tumors models. The in vitro results revealed a significant reduction on cell viability, migration, DNMT activity and displayed lower levels of global DNA methylation in BC cell lines after liraglutide treatment...
September 14, 2021: Chemico-biological Interactions